Arsenic trioxide plus chemo for p53-mutated childhood cancer
Treatments studied
Part of Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests if adding arsenic trioxide to standard chemotherapy can help children with cancers that have a certain p53 gene change. The goal is to see if the drug can reactivate the broken p53 protein to fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a cancer that is confirmed by a biopsy.
- Your child must be 18 years old or younger.
- A specific change in the p53 gene (found in the tumor or inherited) must be present, and it should be the type that can be fixed by the drug arsenic trioxide.
- The tumor must be measurable on scans like MRI or CT.
- You and your child must agree to join the trial and sign a consent form.
- Your child must not have a major organ failure, like heart, brain, or kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This trial looks at treatment for children whose leukemia has come back for the first time. It focuses on a specific type of leukemia and risk level to see whether the approach improves outcomes.
This trial tests whether adding arsenic trioxide (a drug) to the standard transplant process can lower the risk of leukemia coming back. It is for people with AML or MDS who have a certain genetic change (TP53 mutation) and are about to have their first stem cell transplant from a matched donor.
Hear when a new Pediatric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.